Pervasip Corp (OTCMKTS: PVSP) is beginning to see some solid movement northbound running 63% on Monday on 123 million shares traded. The stock looks to be making a move out of the triple zeroes as the Company prepares to spin off its cannabis assets; Artizen Corporation into a new separate public Company with PVSP shareholders getting shares in both Company’s. Artizen subsidiary Zen Asset Management LLC operate four licensed cannabis cultivation and one processing facility in Washington. As for PVSP management is currently evaluating a number of potential targets for acquisition upon completion of the Artizen spin-off. On Monday the Company tweeted that news concerning its forward strategy is forthcoming this week!
PVSP has a storied history on the bulletin boards and saw a historic rise during the summer of 2021. Still trading very close to its 52-week lows following a significant reversal, PVSP has an enormous investor following and can be highly liquid. This stock can trade very significant volume and if this upwards momentum continues many will be jumping back in. Management is currently working with its auditors to complete the required financial audits, including one for Pervasip on a consolidated basis and another separate for Artizen on a consolidated basis. Once complete, a Form 10 Registration Statement will be filed with the SEC for Artizen to initiate the spin-off process. We will be updating on PVSP when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Pervasip Corp
(OTCMKTS: PVSP) is a developer of companies and technologies in high value emerging markets, owns Artizen Corporation and its subsidiary, Zen Asset Management LLC, a diversified asset management company founded to acquire, develop, and support companies and technologies in the cannabis industry. ZAM’s existing clients operate four licensed cannabis cultivation and one processing facility in Washington. Most of the biomass produced by these independent cultivators has been sold historically under the Artizen™ brand, including all-time top selling products in flower in Washington state.
On January 17 PVSP announced it will spin-off 100% of its wholly owned subsidiary, Artizen Corporation as a separate public company, with an anticipated record date between July 1, 2023, and September 30, 2023. As a result of the spin-off, all Pervasip shareholders of record as of the designated record date shall receive shares in the newly public Artizen in proportion to their ownership in Pervasip. Artizen conducts 100% of Pervasip’s cannabis business segment operations through its Zen Asset Management LLC subsidiary.
$PVSP Announcement re forward strategy forthcoming this week! We are very excited about our plans!
— Pervasip Corp (@PervasipC) February 27, 2023
To Find out the inside Scoop on PVSP Subscribe to Newsytrends.com Right Now by entering your Email in the box below
$PVSP added more 0006.
The CEO confirms:
Share reduction and a name change. pic.twitter.com/FCYDxzXRvG— Penny Whale (@WhalePenny) February 27, 2023
PVSP management is positioning the Company for expansion. According to German Burtscher, Chairman and Chief Executive Officer of Pervasip and Artizen: “Spinning out Artizen will allow us to properly capitalize the business to take advantage of multiple expansion opportunities to build on our existing foundation.”
The Company is working with its auditors to complete the required financial audits, including one for Pervasip on a consolidated basis and another for Artizen on a consolidated basis. Once complete, a Form 10 Registration Statement will be filed with the SEC for Artizen to initiate the spin-off process. Additional information regarding the status and timing of the transaction and the various required regulatory and other approvals will be provided as it becomes available. Pervasip has commenced evaluation of potential targets for acquisition upon completion of the Artizen spin-off.
$PVSP lots of excitement today before the news later this week.
The weekly chart is wide open for a BIG reversal. https://t.co/fnKZgBIINY pic.twitter.com/q7CAULAQ7q
— Penny Whale (@WhalePenny) February 27, 2023
For More on PVSP Subscribe Right Now!
Currently trading at a $2.6 million market valuation PVSP os is 5,329,231,963 with 3,870,314,124 shares in the public float according to OTCMarkets. The Company is doing significant revenues via its Artizen subsidiary reporting $4.3 million in sales for the 3 months ended August 31, 2022. PVSP is an exciting story developing in small caps; the Company has history of big moves and high liquidity and recently reversed off 52 week lows. As stated if the upward momentum continues PVSP will have a lot of buyers. Recently the Company stated they are evaluating a number of potential targets for acquisition and on Monday they tweeted that news concerning its forward strategy is forthcoming this week. We will be updating on PVSP when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in PVSP either long or short and we have not been compensated for this article.
Lucira was up 264% on Monday after the Company announced the FDA granted emergency use authorization (EUA) for its Lucira COVID-19 & Flu Home Test for over the counter (OTC) use at home and other non-laboratory sites. Lucira’s COVID-19 & Flu Home Test represents a breakthrough in diagnostic testing as the first at-home combination COVID-19 and Flu test, and as the first Flu test for OTC use at home in the United States in history. Until today, American consumers have never before been able to self-diagnose Flu at home. 
The Lucira COVID-19 & Flu Home Test is not an antigen test. It is a molecular, nucleic acid amplification (NAAT) test that utilizes the same platform and device design as both of Lucira’s commercialized FDA authorized COVID-19 tests to provide independent diagnoses for COVID-19, Flu A and Flu B. The lab-quality single-use test fits in the palm of your hand, runs on 2 AA batteries, and with one shallow nasal swab provides a positive or negative result for COVID-19, Flu A and Flu B in 30 minutes or less. Each Lucira test contains everything needed to run a single test. There is no separate reader or instrument to purchase and maintain. The easy-to-use, all-in-one combination test delivers results in 30 minutes or less from one shallow nasal swab.
Lucira believes that a single test for both COVID-19 and Flu can be a powerful tool given how similar the two viruses appear. “COVID-19 and Flu look the same, feel the same, spread the same and, unfortunately, can still kill the same,” underscored Dr. Davey Smith, Head of the Division of Infectious Disease and Global Public Health at the University of California – San Diego. “Having an at-home molecular test now available should really help people know how to keep their families safe and seek appropriate treatment when they’re ill.”
Lucia CEO Erik Engelson stated: “Our small but experienced team at Lucira has again demonstrated the versatility of our technology platform by introducing this first-of-its-kind innovation in clinically relevant at-home diagnostics to the marketplace. The authorization of the COVID-19 & Flu Home Test with OTC label is another example of how Lucira is helping to transform the future promise of home-based, fast, accurate diagnostics into a reality. Many people are not aware that prescription antiviral medications exist for the treatment of Flu as well as for Covid. But we believe an accurate diagnosis, early in the course of infection is mandatory for effective use of such medications. Prescription and fulfillment over telehealth is convenient and safe, especially when at-home diagnoses take place using a test such as the Lucira COVID-19 & Flu Home Test. We regret that we had no option but to file for Chapter 11 bankruptcy and that this occurred days before we received regulatory authorization. Unfortunately we were unable to bridge what became a protracted authorization cycle time within our current capital structure and it remained unclear to us when the regulatory authorization would come through, despite working closely with FDA. The Lucira COVID-19 & Flu Home Test would have been especially useful during the recent, severe respiratory season, and we had produced inventory for an anticipated autumn 2022 launch. We remain confident in the role that the new test can play in future respiratory seasons and are honored to have received the first authorization for such a home test. We appreciate the diligent work of the FDA team as they refined requirements during the review cycle.”
Premier Biomedical Inc (OTCMKTS: BIEI) was incorporated in the State of Nevada on May 10, 2010. Pursuant to a holding company reorganization of August 2020, the publicly traded company became Premier Holding Corp. In December the Company announced its reorganization as 
Operating out of its 12,000 sq ft light industrial facility, Nova Graphene Ballistics ‘s graphene can be defined as a single layer of carbon atoms bonded together in a hexagonal, sheetlike structure. Nova Graphene Ballistics has partnered with Nova Graphene Inc., and Nova Graphene Canada to employ its proprietary production methodology to manufacture a revolutionary, proprietary 3D-printed ballistic armor. The revolutionary garments are designed as lightweight, perfectly fitting protective wear, virtually impenetrable. 
On January 19 Nova Graphene Ballistics, Inc. announced the following steps, in pursuit of its first initiative 3D-printed Graphene Ballistic Plate Production, including the prototype, with regard to novel graphene production. With the timing of completing each step to be reported shortly, some of the highlights are as follows: Novel 3D printing filaments, Customized set-up & modifications to our high-temperature printers to enable optimized performance, Proprietary software to convert 3D body & equipment scans to printable ballistic plate files, Novel internal plate architecture, Marriage of the custom 3D-printed base plate with an integrated strike face (designed to tumble incoming rounds for efficient energy dispersion), and Prototype delivery to DARPA, consistent with our white paper. Nova Graphene graphenes and novel additive formulations are integrated into the production processes of other products to make them stronger, harder, lighter, and more fire-resistant.
In August Headsup
Headsup also completed another major milestone with the acquisition of 
Provectus proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in the drug product candidates of Provectus’ clinical development programs and the preclinical formulations of the Company’s drug discovery programs. Importantly, Provectus’ pharmaceutical-grade RBS displays different therapeutic effects at different concentrations and can be formulated for delivery by different routes of administration. The International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) selected “rose bengal sodium” for the nonproprietary name of the Company’s API.
Provectus believes that it is the first entity to advance an RBS formulation into clinical trials for the treatment of a disease, such as those trials reported on the clinical trials registry ClinicalTrials.gov. Provectus also believes that it is the first and only entity to date to successfully, reproducibly, and consistently make pharmaceutical-grade RBS at a purity of nearly 100%.
Ocean Biomedical’s core portfolio, built from relationships with these leading institutions, is currently focused in three critical areas: oncology, pulmonary fibrosis, and infectious disease. Each include new target discoveries that will enable first-in-class drug and vaccine candidates, developed through past and ongoing grants totaling $123.9 million. All three represent large markets with tremendous unmet medical needs.
The Company is led by Elizabeth Ng, Chief Executive Officer, a proven biotechnology veteran. Dr. Jack Elias, former Dean of Medicine at Brown University and Professor of Translational Sciences, Medicine, and Molecular Biology at the Warren Alpert Medical School Brown University, and Dr. Jake Kurtis, the current chair of pathology and laboratory medicine at Brown, each Company co-founders, will retain their positions as Scientific Advisory Board Chair and Chief Scientist, respectively. 
Hemp has established a network of industry professionals in every segment of the industrial hemp industry and continues to advance an ever-growing portfolio of revenue and value-generating synergistic businesses. Hemp also has its full line of CBD/CBG/CBN products that includes CBD-CBG Topical Pain Relief Roll-on, CBD/CBG Natural Coffee Enhancers, CBD/CBG Tinctures, and CBDa/CBGa/CBD/CBG/CBN Capsules. Hemp, Inc. also has the means to produce hempcrete, horse bedding, hemp bio-plastics, and more.
Hemp Inc.’s CBD/CBG Tinctures are made from hemp isolate (99% pure), fractionated organic coconut oil (MCT oil) and USP grade β cyclodextrin (BCD), which increases the body’s ability to quickly absorb the cannabinoids in the intestines. This same tincture (minus the BCD) is used in Hemp Inc.’s Coffee Enhancer. Hemp Inc. also has a potent Pain Relief Roll-on that has received rave reviews from users. For people who prefer capsules, Hemp Inc. offers CBDA/CBGA capsules, CBD/CBG capsules, as well as CBD/CBG/CBN capsules.
At Hemp’s Spring Hope, N.C. facility, the Company produces 
On February 16 HEMP announces its largest industrial product sale to date. Four semi-trucks hauled 120,000 pounds of Hemp, Inc.’s DrillWall™, the only all-natural kenaf/hemp Loss Circulation Material (LCM) blend of its kind on the market, for the oil and gas well drilling industries. The sales agreement was initially signed at the end of 2019 through Hemp, Inc.’s subsidiary, Industrial Hemp Manufacturing, LLC, (IHM), and was set to sell 1 million pounds worth of DrillWall™ over the course of one year. However, due to the COVID-19 global pandemic rearing its ugly head (or ugly spikes), there was a disruption in the distribution.
Bioelectronics Corp (OTCMKTS: BIEL) is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. The Company’s innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications. The Company’s current OTC product line is ActiPatch® Musculoskeletal Pain Therapy, RecoveryRx® Postoperative and Chronic Wounds Therapy, which are sold by or on the order of medical professionals. Bioelectronics operates out of its 4,100 sq. ft headquarters in Frederick, Maryland.
The ActiPatch®
According to the Company most recent quarterly reported filed on November 15, 2022; ActiPatch® technology has the potential to become the standard of care throughout the healthcare continuum across the OTC and healthcare markets. BioElectronics’ technology offers significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications. In July of 2022 the Company reported that in a recently published paper, a RCT study of temporomandibular joint disorders (TMD) found that ActiPatch, provided better and longer pain relief than a combination of an NSAID and a commercially available muscle relaxant, Myospas. TMD affects approximately 5%–12% of the overall population and thus represents another potential market that we plan to explore. 
RecoveryRx
BioElectronics continues to be focused on expansion and has established distribution agreements with distributors in the United Kingdom, Sweden, Southeast Asia, Italy, Mexico, Spain and Australia. They also have a commercial partnership agreement with Scott Specialties Inc. to ActiPatch under the DonJoy® Advantage product line with DJO’s DonJoy Advantage (DJA) line of orthopedic appliances and sold as an EME Knee Wrap and an EME Back Wrap, “powered by ActiPatch”. They also executed an OEM agreement with KT Health, incorporating BioElectronics’ ActiPatch® technology into KT Health’s KT Recovery+® product line, being marketed and distributed under the proprietary trade name KT Recovery+ WAVETM. More recently the Company signed an agreement with Stada, a leading manufacturer of high-quality pharmaceuticals, who will be distributing ActiPatch to augment their non-prescription consumer healthcare products.
The Converge Acquisition has proven to be the catalyst for Troika
Troika is now doing big numbers; On November 14 Troika reported record revenues of $120 million and adjusted EBITDA of $10.1 million for its quarter ended September 30, 2022, representing a revenue increase of 1,335% quarter over quarter. Troika also reported an operating income of $6.3 million and reported its first net income since going public in April 2021. Over 90% of the Company’s revenues come from its Converge business, which saw organic growth from existing clients, and substantial growth, most notably, in performance solutions. 
Sid Toama, TMG’s Chief Executive Officer, stated, “We have refined our business model since the acquisition of Converge Direct in second quarter 2022 to take advantage of sustainably higher margin opportunities to meaningfully improve strategic and financial results. We believe that now is the time to explore opportunities to optimize our capital structure and have engaged a market leader in Jefferies to maximize our ability to deliver shareholder value. We have worked closely with our senior secured lender over the last eight months and recently announced an Amended and Restated Limited Waiver, which provides us with time to explore different means to enhance shareholder value”.
The Company’s large 39,946-hectare 100% owned Patterson Lake North property (PLN) is located just within the south-western edge of the Athabasca Basin in proximity to Fission Uranium’s Triple R and NexGen Energy’s Arrow high-grade world class uranium deposits which is poised to become the next major area of development for new uranium operations in northern Saskatchewan. PLN is accessed by Provincial Highway 955, which transects the property, and the new JR Zone uranium discovery is located 23km northwest of Fission Uranium’s Triple R deposit.
Last week the Company reported scintillometer results from four additional holes of the ongoing 20-hole winter drill program at the JR Zone on the Patterson Lake North (“PLN”) Property, including three high grade intercepts. Drill hole PLN23-050 was collared as a step out on line 045S and intersected the widest mineralized interval to date over 21.0m, including 3.19m of composite radioactivity with >10,000 cps and a peak of 57,100 cps at a downhole depth of 255.0m. PLN23-052 stepped out further to line 060S and resulted in 11.0m of mineralization, including 1.70m of continuous radioactivity with >10,000 cps and a peak of 53,600 cps. Infill drillhole PLN23-053 on line 030S intersected radioactivity over a 9.5m interval between 245.5m and 255.0m including 2.10m of composite radioactivity with >10,000 cps and a peak of 48,100 cps.
Raymond Ashley, Vice President Exploration, commented: “The technical team is delighted to announce scintillometer results of step out hole PLN23-050 on line 045S where mineralization was encountered over a 21.0m interval within the A1 main shear zone, including the high grade core. The Company is continuing with disciplined step out drilling and growing the JR Zone further along strike to the south, which has now been defined over a total length of 75 meters to section line 060S where PLS23-052 intersected high grade mineralization with up to 53,600 cps. Although PLS23-051 on section line 00SN tested the MSZ closer to the Athabasca Unconformity and did encounter radioactivity, we anticipate focusing the remaining winter program on basement hosted mineralization. The JR Zone continues to impress with high grade intercepts as we define it along strike while also building some width with infill drill holes.”